PolyPid Ltd. (PYPD): Price and Financial Metrics
GET POWR RATINGS... FREE!
PYPD Stock Price Chart Interactive Chart >
PYPD Price/Volume Stats
| Current price | $8.23 | 52-week high | $16.50 |
| Prev. close | $8.52 | 52-week low | $6.95 |
| Day low | $8.10 | Volume | 4,326 |
| Day high | $8.52 | Avg. volume | 48,999 |
| 50-day MA | $8.07 | Dividend yield | N/A |
| 200-day MA | $9.53 | Market Cap | 140.29M |
PolyPid Ltd. (PYPD) Company Bio
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.
Latest PYPD News From Around the Web
Below are the latest news stories about PolyPid Ltd that investors may wish to consider to help them evaluate PYPD as an investment opportunity.
PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare ConferencePETAH TIKVA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29 at 02:00 pm EDT. |
PolyPid Shares Preclinical Data Of OncoPLEX Program For Brain TumorPolyPid Ltd (NASDAQ: PYPD ) has announced preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program. OncoPLEX is designed to provide controlled local exposure to docetaxel, one of the most widely used chemotherapy agents. OncoPLEX induced strong inhibition of tumor growth and recurrence in a partially resected Full story available on Benzinga.com |
PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain CancerPETAH TIKVA, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced positive preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program. |
PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma CongressVirtual Presentation to be led by PolyPid Co-Founder and CSO on August 28, 2021 PETACH TIKVA, Israel, Aug. 17, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical |
PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateRecruitment Progressing as Planned with Over 3 00 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery |
PYPD Price Returns
| 1-mo | -4.41% |
| 3-mo | -13.37% |
| 6-mo | -12.91% |
| 1-year | -34.68% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -16.87% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...